Constantinos T Sofocleous1, Elena N Petre2, Mithat Gonen3, Diane Reidy-Lagunes4, Ivan K Ip2, William Alago2, Anne M Covey2, Joseph P Erinjeri2, Lynn A Brody2, Majid Maybody2, Raymond H Thornton2, Stephen B Solomon2, George I Getrajdman2, Karen T Brown2. 1. Section of Interventional Radiology and Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., Suite H 118, New York, NY 10065. Electronic address: sofoclec@mskcc.org. 2. Section of Interventional Radiology and Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., Suite H 118, New York, NY 10065. 3. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., Suite H 118, New York, NY 10065. 4. Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., Suite H 118, New York, NY 10065.
Abstract
PURPOSE: To identify factors affecting periprocedural morbidity and mortality and long-term survival following hepatic artery embolization (HAE) of hepatic neuroendocrine tumor (NET) metastases. MATERIALS AND METHODS: This single-center, institutional review board-approved retrospective review included 320 consecutive HAEs for NET metastases performed in 137 patients between September 1996 and September 2007. Forty-seven HAEs (15%) were performed urgently to manage refractory symptoms in inpatients (urgent group), and 273 HAEs (85%) were elective (elective group). Overall survival (OS) was estimated by Kaplan-Meier methodology. Complications were categorized per Common Terminology Criteria for Adverse Events, version 4.0. Univariate and multivariate analyses were performed to determine independent predictors for OS, complications, and 30-day mortality. The independent factors were combined to develop clinical risk score groups. RESULTS: Urgent HAE (P = .007), greater than 50% liver replacement by tumor (P < .0001), and extrahepatic metastasis (P = .007) were independent predictors for shorter OS. Patients with all three risk factors had decreased OS versus those with none (median, 8.5 vs 86 mo; P < .001). Thirty-day mortality was significantly lower in the elective (1%) versus the urgent group (8.5%; P = .0009). There were eight complications (3%) in the elective group and five (10.6%) in the urgent group (P = .03). Male sex and urgent group were independent factors for higher 30-day mortality rate (P = .023 and P =.016, respectively) and complications (P = .012 and P =.001, respectively). CONCLUSIONS: Urgent HAE, replacement of more than 50% of liver by tumor, and extrahepatic metastasis are strong independent predictors of shorter OS. Male sex and urgent HAE carry higher 30-day mortality and periprocedural morbidity risks.
PURPOSE: To identify factors affecting periprocedural morbidity and mortality and long-term survival following hepatic artery embolization (HAE) of hepatic neuroendocrine tumor (NET) metastases. MATERIALS AND METHODS: This single-center, institutional review board-approved retrospective review included 320 consecutive HAEs for NET metastases performed in 137 patients between September 1996 and September 2007. Forty-seven HAEs (15%) were performed urgently to manage refractory symptoms in inpatients (urgent group), and 273 HAEs (85%) were elective (elective group). Overall survival (OS) was estimated by Kaplan-Meier methodology. Complications were categorized per Common Terminology Criteria for Adverse Events, version 4.0. Univariate and multivariate analyses were performed to determine independent predictors for OS, complications, and 30-day mortality. The independent factors were combined to develop clinical risk score groups. RESULTS: Urgent HAE (P = .007), greater than 50% liver replacement by tumor (P < .0001), and extrahepatic metastasis (P = .007) were independent predictors for shorter OS. Patients with all three risk factors had decreased OS versus those with none (median, 8.5 vs 86 mo; P < .001). Thirty-day mortality was significantly lower in the elective (1%) versus the urgent group (8.5%; P = .0009). There were eight complications (3%) in the elective group and five (10.6%) in the urgent group (P = .03). Male sex and urgent group were independent factors for higher 30-day mortality rate (P = .023 and P =.016, respectively) and complications (P = .012 and P =.001, respectively). CONCLUSIONS: Urgent HAE, replacement of more than 50% of liver by tumor, and extrahepatic metastasis are strong independent predictors of shorter OS. Male sex and urgent HAE carry higher 30-day mortality and periprocedural morbidity risks.
Authors: Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria Journal: Hepatology Date: 2011-06-30 Impact factor: 17.425
Authors: C C Solorzano; J E Lee; P W Pisters; J N Vauthey; G D Ayers; M E Jean; R F Gagel; J A Ajani; R A Wolff; D B Evans Journal: Surgery Date: 2001-12 Impact factor: 3.982
Authors: James C Yao; Manisha H Shah; Tetsuhide Ito; Catherine Lombard Bohas; Edward M Wolin; Eric Van Cutsem; Timothy J Hobday; Takuji Okusaka; Jaume Capdevila; Elisabeth G E de Vries; Paola Tomassetti; Marianne E Pavel; Sakina Hoosen; Tomas Haas; Jeremie Lincy; David Lebwohl; Kjell Öberg Journal: N Engl J Med Date: 2011-02-10 Impact factor: 91.245
Authors: Brian L Dunfee; Ahsun Riaz; Robert J Lewandowski; Saad Ibrahim; Mary F Mulcahy; Robert K Ryu; Bassel Atassi; Kent T Sato; Steven Newman; Reed A Omary; Al Benson; Riad Salem Journal: J Vasc Interv Radiol Date: 2009-11-25 Impact factor: 3.464
Authors: C Swärd; V Johanson; E Nieveen van Dijkum; S Jansson; O Nilsson; B Wängberg; H Ahlman; L Kölby Journal: Br J Surg Date: 2009-05 Impact factor: 6.939
Authors: Susan C Pitt; Jaime Knuth; James M Keily; John C McDermott; Sharon M Weber; Hebert Chen; William S Rilling; Edward J Quebbeman; David M Agarwal; Henry A Pitt Journal: J Gastrointest Surg Date: 2008-08-16 Impact factor: 3.452
Authors: Rebecca Zener; Hyukjun Yoon; Etay Ziv; Anne Covey; Karen T Brown; Constantinos T Sofocleous; Raymond H Thornton; F Edward Boas Journal: Cardiovasc Intervent Radiol Date: 2019-01-09 Impact factor: 2.740
Authors: F Edward Boas; Etay Ziv; Hooman Yarmohammadi; Karen T Brown; Joseph P Erinjeri; Constantinos T Sofocleous; James J Harding; Stephen B Solomon Journal: J Vasc Interv Radiol Date: 2017-05-17 Impact factor: 3.464
Authors: Haruyuki Takaki; Tess Litchman; Ann Covey; Franois Cornelis; Majid Maybody; George I Getrajdman; Constantinos T Sofocleous; Karen T Brown; Stephen B Solomon; William Alago; Joseph P Erinjeri Journal: J Gastrointest Cancer Date: 2014-12
Authors: S Grozinsky-Glasberg; G Kaltsas; M Kaltsatou; N Lev-Cohain; A Klimov; V Vergadis; I Uri; A I Bloom; D J Gross Journal: Endocrine Date: 2018-01-30 Impact factor: 3.633
Authors: Etay Ziv; Samuel L Rice; John Filtes; Hooman Yarmohammadi; F Edward Boas; Joseph P Erinjeri; Elena Nadia Petre; Lynn A Brody; Karen T Brown; Anne M Covey; George I Getrajdman; Majid Maybody; Nitya Raj; Constantinos T Sofocleous; Stephen B Solomon; Diane Reidy-Lagunes Journal: J Vasc Interv Radiol Date: 2018-10-19 Impact factor: 3.464
Authors: Elena G Violari; Elena N Petre; Darren R Feldman; Joseph P Erinjeri; Karen T Brown; Stephen B Solomon; Michael I D'Angelica; Constantinos T Sofocleous Journal: Cardiovasc Intervent Radiol Date: 2014-06-18 Impact factor: 2.797